DIGP appears to be rising from the dead. Could it be the zombie stock apocalypse, or the second coming? In any event, I like the momentum. I'm adding to my position, lets go Digipath, to 10 cents and beyond!
Bullish
T
Digipath Files Patent Application for Test to Distinguish Hemp from Drug-type Cannabis Today 9:00 AM ET (PR NewsWire)Print
Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp markets, is pleased to announce that in collaboration with VSSL of Kelowna, BC, has filed a provisional patent application for a Field Testing Kit that can quickly determine whether a plant sample is actually hemp, drug-type THC or drug-type CBD. Source: TD Ameritrade
J
hemp
T
Digipath Benefits from Record Cannabis Sales in Nevada 6/10/19 9:00 AM ET (PR NewsWire)Print
Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, is pleased to announce that The Nevada Department of Taxation has reported marijuana sales results for 2018 and 2019 to date here; showing a continuing increase in volume in the state. This corresponds with the increased demand Digipath is experiencing for its governmentally required cannabis testing services in Nevada.
https://mma.prnewswire.com/media/94753/digipath_inc_logo.jpg In March alone, the State of Nevada reported record cannabis sales of just under $60 million. March is historically a stronger month for legal marijuana transactions with 31 days, and this year had five weekends. March sales surpassed February results for record average sales of $1.9 million per day. Recreational sales were $53.6 million, up to $11.1 million from February, while medicinal sales were off by $800,000. Overall, March 2019 sales grew by 20% compared to March 2018.
Digipath's sales volume increases are reflective of Nevada's overall results, with Digipath's March 2019 revenues increasing by 20% from February 2018.
LAS VEGAS, Dec. 18, 2018 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis and hemp markets, is pleased to announce its support of Congress's Farm Bill, which leg
LAS VEGAS, Dec. 18, 2018 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis and hemp markets, is pleased to announce its support of Congress's Farm Bill, which leg
finance.yahoo.com
E
Really excited about Digipath's business strategies as we go forward into the next earnings quarter!.
T
Digipath, Inc. (OTCQB: DIGP) ("DIGP" or the "Company"), a service-oriented independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that the Company's GroSciences subsidiary has made significant progress in developing its Tru-Hemp ID project, with commercial availability targeted for late 2019/early 2020. GroSciences is Digipath's wholly owned subsidiary which combines years of testing data and proprietary research to create "The Science to Succeed" for clients wanting expert guidance on formulations, identification, and more.
As previously reported, Digipath, via GroSciences, has been developing a field testing kit for hemp, cannabis and other related products with a myriad of applications from law enforcement to growers. GroSciences has now successfully completed the in-house testing of its prototype Tru-Hemp ID DNA-based assay kits at two separate laboratories. Tru-Hemp ID distinguishes industrial hemp which is legal under the 2018 Farm Bill, from drug-type cannabis. The kit is expected to serve a growing need in the burgeoning hemp industry since legal hemp is not visually distinguishable from high-THC marijuana, a Schedule I Controlled Substance.
Currently, GroSciences plans to beta-test Tru-Hemp ID in August in Vermont, New York and North Carolina, with talks underway with hemp growers and regulators in Oregon, Colorado and California.
"We have made significant progress in developing GroSciences' molecular assay, Tru-Hemp ID," stated Chief Science Officer for Digipath, Dr. Cindy Orser. "In addition to developing the technology for the Tru-Hemp ID testing kit, we are partnering with leading hemp growers to conduct independent testing using our technology, which we expect to help accelerate our path to market and commercial acceptance of our testing kit."
"The deployment of Tru-Hemp ID in the commercial marketplace will provide Digipath with a new revenue stream," added Todd Denkin, CEO, Digipath. "Our goal is to not just be a leading testing lab, but a leading canna-tech company."
About Digipath, Inc. (OTCQB: DIGP) Digipath, Inc., is a cannabis data company and independent cannabis-testing firm that supports the cannabis industry's best practices for reliable testing, data acquisition and analysis.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
F
Hemp is underwriting digipaths expansion, buying in at this sp is sweet. It now has a significant revenue stream and the potential to access additional clients, it will insure stable growth. Not much more you can ask.
T
Press Release: Digipath to Acquire Cannabis Technology Firm VSSL Enterprises Ltd. 9:37 am ET September 30, 2019 (Dow Jones) Print Digipath to Acquire Cannabis Technology Firm VSSL Enterprises Ltd.
VSSL CEO Kyle Remenda Appointed Digipath Chief Executive Officer
LAS VEGAS, NV, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Digipath, Inc. (OTCQB: DIGP), is pleased to announce it has entered into a binding letter of intent for the acquisition of VSSL Enterprises Ltd. ("VSSL"), a British Columbia based cannabis genomics, plant sciences and consulting firm. The acquisition is expected to provide Digipath with a wealth of cannabis data, technology and intellectual property, including in excess of a thousand hemp and cannabis genotypes. The letter of intent provides for the acquisition of 100% of VSSL's outstanding shares of capital stock for consideration consisting of six million shares of Digipath common stock and a cash payment of $200,000, and is subject to the execution of definitive agreements.
VSSL builds predictive tools for the cannabis industry. Whether it's for a breeder, cultivator or processor, understanding the genetic basis of key traits such as yield, expression of secondary metabolites or disease resistance can provide a competitive advantage to its clients by allowing rapid decision making and process optimization. VSSL uses molecular and bioinformatics tools to deliver unique solutions suited to its customers' diverse germplasm and business models.
Effective upon signing the letter of intent, VSSL Chief Executive Officer, Kyle Remenda was appointed to serve as Digipath's Chief Executive officer. Todd Denkin, the former CEO, has resigned his positions with Digipath to pursue other opportunities. Under Mr. Denkin's leadership, Digipath has become the leading cannabis testing laboratory in Las Vegas, a leader in data analysis and a recognized brand around the country. He will continue to consult with the Company through the end of 2019.
Mr. Remenda is a passionate advocate within the medical marijuana industry. Under Kyle's leadership, VSSL has become a trusted source of technology and genotype technology and consulting. Before starting VSSL, Mr. Remenda worked in the medical marijuana industry with established legal grow operations in North America. He and the VSSL team bring a wealth of expertise in plant breeding, genetics and production craft.
LAS VEGAS, Jan. 22, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp markets, is pleased to announce that it has entered into an agreement t
LAS VEGAS, Jan. 22, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp markets, is pleased to announce that it has entered into an agreement t
finance.yahoo.com
j
we are building for a nice run news should be out in may updating revenue and plans to open up shop in California
C
digp has really turned things around, I'm sitting here thinking: a year or so from now, what will stock price be? 50 cents? 1 dollar? 2 dollars? 3 dollars?
N
Watching this one ....
B
Proxy: To approve an amendment to the Company's Articles of Incorporation increasing the number of authorized shares of common stock from 90,000,000 shares to 250,000,000 shares. FOR; AGAINST; OR ABSTAIN
M
I think this company will be fine once the dust settles. Glad I bought that giant dip
Z
Digipath Inc. is a Nevada company that tests medical and recreational Cannabis products. It started as a medical testing company and has remade itself into an independent cannabis testing lab. The company is thinly traded but volume has recently picked up. It appears that they should have a good quarter as the Nevada regulations require testing from a sample of every 7 lbs that are sold. Any one looked into this company?
m
Anyone else think it is interesting that Denkin is leaving the company? IDK seems like Digipath was his passion project, and to just leave without talking about it seems strange to me.
ORLANDO, FL / ACCESSWIRE / January 9, 2019 / The explosion of the cannabis and hemp market in the United States is no secret to investors. Stocks related to these industries have been among some of the most followed in the market as the watershed ev
ORLANDO, FL / ACCESSWIRE / January 9, 2019 / The explosion of the cannabis and hemp market in the United States is no secret to investors. Stocks related to these industries have been among some of the most followed in the market as the watershed ev
Today 9:00 AM ET (PR NewsWire)Print
Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp markets, is pleased to announce that in collaboration with VSSL of Kelowna, BC, has filed a provisional patent application for a Field Testing Kit that can quickly determine whether a plant sample is actually hemp, drug-type THC or drug-type CBD. Source: TD Ameritrade
6/10/19 9:00 AM ET (PR NewsWire)Print
Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, is pleased to announce that The Nevada Department of Taxation has reported marijuana sales results for 2018 and 2019 to date here; showing a continuing increase in volume in the state. This corresponds with the increased demand Digipath is experiencing for its governmentally required cannabis testing services in Nevada.
https://mma.prnewswire.com/media/94753/digipath_inc_logo.jpg
In March alone, the State of Nevada reported record cannabis sales of just under $60 million. March is historically a stronger month for legal marijuana transactions with 31 days, and this year had five weekends. March sales surpassed February results for record average sales of $1.9 million per day. Recreational sales were $53.6 million, up to $11.1 million from February, while medicinal sales were off by $800,000. Overall, March 2019 sales grew by 20% compared to March 2018.
Digipath's sales volume increases are reflective of Nevada's overall results, with Digipath's March 2019 revenues increasing by 20% from February 2018.
https://mma.prnewswire.com/media/94753/digipath_inc_logo.jpg
As previously reported, Digipath, via GroSciences, has been developing a field testing kit for hemp, cannabis and other related products with a myriad of applications from law enforcement to growers. GroSciences has now successfully completed the in-house testing of its prototype Tru-Hemp ID DNA-based assay kits at two separate laboratories. Tru-Hemp ID distinguishes industrial hemp which is legal under the 2018 Farm Bill, from drug-type cannabis. The kit is expected to serve a growing need in the burgeoning hemp industry since legal hemp is not visually distinguishable from high-THC marijuana, a Schedule I Controlled Substance.
Currently, GroSciences plans to beta-test Tru-Hemp ID in August in Vermont, New York and North Carolina, with talks underway with hemp growers and regulators in Oregon, Colorado and California.
"We have made significant progress in developing GroSciences' molecular assay, Tru-Hemp ID," stated Chief Science Officer for Digipath, Dr. Cindy Orser. "In addition to developing the technology for the Tru-Hemp ID testing kit, we are partnering with leading hemp growers to conduct independent testing using our technology, which we expect to help accelerate our path to market and commercial acceptance of our testing kit."
"The deployment of Tru-Hemp ID in the commercial marketplace will provide Digipath with a new revenue stream," added Todd Denkin, CEO, Digipath. "Our goal is to not just be a leading testing lab, but a leading canna-tech company."
About Digipath, Inc. (OTCQB: DIGP) Digipath, Inc., is a cannabis data company and independent cannabis-testing firm that supports the cannabis industry's best practices for reliable testing, data acquisition and analysis.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
9:37 am ET September 30, 2019 (Dow Jones) Print
Digipath to Acquire Cannabis Technology Firm VSSL Enterprises Ltd.
VSSL CEO Kyle Remenda Appointed Digipath Chief Executive Officer
LAS VEGAS, NV, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Digipath, Inc. (OTCQB: DIGP), is pleased to announce it has entered into a binding letter of intent for the acquisition of VSSL Enterprises Ltd. ("VSSL"), a British Columbia based cannabis genomics, plant sciences and consulting firm. The acquisition is expected to provide Digipath with a wealth of cannabis data, technology and intellectual property, including in excess of a thousand hemp and cannabis genotypes. The letter of intent provides for the acquisition of 100% of VSSL's outstanding shares of capital stock for consideration consisting of six million shares of Digipath common stock and a cash payment of $200,000, and is subject to the execution of definitive agreements.
VSSL builds predictive tools for the cannabis industry. Whether it's for a breeder, cultivator or processor, understanding the genetic basis of key traits such as yield, expression of secondary metabolites or disease resistance can provide a competitive advantage to its clients by allowing rapid decision making and process optimization. VSSL uses molecular and bioinformatics tools to deliver unique solutions suited to its customers' diverse germplasm and business models.
Effective upon signing the letter of intent, VSSL Chief Executive Officer, Kyle Remenda was appointed to serve as Digipath's Chief Executive officer. Todd Denkin, the former CEO, has resigned his positions with Digipath to pursue other opportunities. Under Mr. Denkin's leadership, Digipath has become the leading cannabis testing laboratory in Las Vegas, a leader in data analysis and a recognized brand around the country. He will continue to consult with the Company through the end of 2019.
Mr. Remenda is a passionate advocate within the medical marijuana industry. Under Kyle's leadership, VSSL has become a trusted source of technology and genotype technology and consulting. Before starting VSSL, Mr. Remenda worked in the medical marijuana industry with established legal grow operations in North America. He and the VSSL team bring a wealth of expertise in plant breeding, genetics and production craft.
50 cents?
1 dollar?
2 dollars?
3 dollars?
FOR; AGAINST; OR ABSTAIN